HOWL

Werewolf Therapeutics Inc

HOWL, USA

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

https://werewolftx.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
HOWL
stock
HOWL

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why MSN

Read more →
HOWL
stock
HOWL

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 17,858 Shares MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$6.1667

Analyst Picks

Strong Buy

4

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.70

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-55.28 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-20.56 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

1.69

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 51.40% of the total shares of Werewolf Therapeutics Inc

1.

RA Capital Management, LLC

(14.6107%)

since

2025/06/30

2.

Mpm Asset Management, LLC

(9.4248%)

since

2025/06/30

3.

MPM Oncology Impact Management LP

(5.2676%)

since

2025/06/30

4.

Bank of America Corp

(4.6557%)

since

2025/06/30

5.

Vanguard Group Inc

(2.839%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(1.9169%)

since

2025/07/31

7.

Millennium Management LLC

(1.5235%)

since

2025/06/30

8.

Sphera Funds Management Ltd.

(1.3707%)

since

2025/06/30

9.

DC Funds, LP

(1.2882%)

since

2025/06/30

10.

Partner Fund Management LP

(0.8771%)

since

2025/06/30

11.

Jane Street Group LLC

(0.8199%)

since

2025/06/30

12.

BlackRock Inc

(0.7916%)

since

2025/06/30

13.

Geode Capital Management, LLC

(0.7172%)

since

2025/06/30

14.

Renaissance Technologies Corp

(0.6917%)

since

2025/06/30

15.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6228%)

since

2025/07/31

16.

Alyeska Investment Group, L.P.

(0.5154%)

since

2025/06/30

17.

Goldman Sachs Group Inc

(0.4974%)

since

2025/06/30

18.

Fidelity Extended Market Index

(0.363%)

since

2025/07/31

19.

State Street Corp

(0.2606%)

since

2025/06/30

20.

A4Investments SICAV SIF ACCI IlanaA2EURH

(0.2575%)

since

2025/08/31

21.

Marshall Wace Asset Management Ltd

(0.227%)

since

2025/06/30

22.

Bridgeway Capital Management, LLC

(0.2231%)

since

2025/06/30

23.

Bridgeway Ultra-Small Company Market

(0.2187%)

since

2025/06/30

24.

AQR Capital Management LLC

(0.2016%)

since

2025/06/30

25.

Y-Intercept (Hong Kong) Ltd

(0.1846%)

since

2025/06/30

26.

Vifag 2002 SICAV

(0.1531%)

since

2025/07/31

27.

Fidelity Total Market Index

(0.1202%)

since

2025/07/31

28.

Extended Equity Market Fund K

(0.1199%)

since

2025/06/30

29.

Fidelity Series Total Market Index

(0.0932%)

since

2025/07/31

30.

NT Ext Equity Mkt Idx Fd - L

(0.0867%)

since

2025/06/30

31.

Northern Trust Extended Eq Market Idx

(0.0867%)

since

2025/06/30

32.

Spartan Extended Market Index Pool F

(0.0757%)

since

2025/07/31

33.

NT Col R2000 Val Idx Fd -DC -L -TierFour

(0.0559%)

since

2025/03/31

34.

NT Ext Equity Mkt Idx Fd - NL

(0.0539%)

since

2025/06/30

35.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0419%)

since

2025/06/30

36.

Spartan Total Market Index Pool G

(0.0406%)

since

2025/07/31

37.

Fidelity Nasdaq Composite Index

(0.0281%)

since

2025/07/31

38.

State Street Russell 2000 Value CIT

(0.0273%)

since

2025/03/31

39.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0245%)

since

2025/06/30

40.

Vanguard U.S. Eq Idx £ Acc

(0.0226%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.36

EPS Estimate

-0.388

EPS Difference

0.028

Surprise Percent

7.2165%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(1.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.